^
Association details:
| Biomarker: | TNFRSF8 expression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) + Adcetris (brentuximab vedotin) (Microtubule inhibitor, CD30-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas
Excerpt:
In the PMBCL cohort of 22 evaluable patients with a median follow-up of 30 months (95% CI: 23-46), the 2-year progression-free survival rate was 86% (95% CI: 62-95) with a 2-year overall survival of 100% (Figure 2)....BV-R-CHP with or without consolidative radiation is a feasible and active frontline regimen for CD30+ B-cell lymphomas.
Secondary therapy:
doxorubicin hydrochloride + cyclophosphamide + prednisone
DOI:
https://doi.org/10.3324/haematol.2019.238675
Trial ID:
